Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Roche Holding AG Basel American Depositary Shares (OP: RHHBY )

29.46 -0.29 (-0.97%)
Streaming Delayed Price Updated: 2:12 PM EDT, May 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,030,643
Open 29.71
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 29.75
Today's Range 29.20 - 29.73
52wk Range 29.53 - 40.48
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Can Ocugen Stock Keep Churning Higher?
This tiny biotech caught fire in 2024. Can it sustain the momentum? 
Via The Motley Fool
Why Is Penny Stock HOOKIPA Pharma Trading Higher On Wednesday?
HOOKIPA Pharma secures FDA clearance for its innovative HB-700 therapeutic vaccine targeting KRAS-mutated cancers. Learn about its broad impact on lung, colorectal, and pancreatic cancers, achieving... 
Via Benzinga
Exposures Product Safety

Performance

YTD
-18.95%
-18.95%
1 Month
-7.79%
-7.79%
3 Month
-16.16%
-16.16%
6 Month
-10.37%
-10.37%
1 Year
-25.32%
-25.32%

More News

Read More
2 Small-Cap Growth Stocks With Room To Run
Via The Motley Fool
FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer
From Genentech
Via Business Wire
Genentech’s Subcutaneous Ocrevus One-Year Data Demonstrates Near-Complete Suppression of Clinical Relapses and Brain Lesions in Patients With Progressive and Relapsing Forms of MS
From Genentech
Via Business Wire
Roche's Lymphoma Drug With Chemo Extends Survival In Pretreated Patients
Via Benzinga
Genentech’s Columvi Meets Primary Endpoint of Overall Survival in People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Phase III STARGLO Study
From Genentech
Via Business Wire
Looking for an Easy Way to Earn Passive Income? This Vanguard ETF Pays a Dividend Yield of Nearly 4.9%.
Via The Motley Fool
Topics ETFs
Why Roche Holdings Stock Popped Today
Via The Motley Fool
Can Recursion Pharmaceuticals Stock Double in 5 Years? Here's What It Would Take.
Via The Motley Fool
Analysts Express Confidence in Alnylam's Hypertension Drug Despite Mixed Trial Data
Via Benzinga
Why Sarepta's First-Quarter Report Is Already Dead In The Water: Analyst
Via Investor's Business Daily
Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback
Via Investor's Business Daily
Exposures Product Safety
Hot Stocks: The 3 Best Opportunities for Investing in Weight Loss Drugs
Via InvestorPlace
Why Is European Pharma Giant Argenx Valued At Over $20B Trading Higher On Thursday?
Via Benzinga
Swiss Healthcare Manufacturing Firm Lonza Bolsters Biologics Manufacturing Capacity With Roche's US Facility Acquisition For $1.2B
Via Benzinga
FDA Approves BeiGene's First Drug Candidate Produced Through Its Immuno-Oncology Program For Esophageal Cancer
Via Benzinga
Exposures Product Safety
Top Wall Street Analysts Flag US Market Concentration Anxiety, Advise Investors To Adopt 'Barbell Approach'
Via Benzinga
Pharma Stock Roundup: Novo Nordisk's New Obesity Pill Data, Roche, AstraZeneca's Pipeline Updates
Via Talk Markets
Exposures Product Safety
FDA Conditionally Approves Expanded Use Of BeiGene's Combination Drug For Certain Type Of Blood Cancer
Via Benzinga
Exposures Product Safety
Roche/Alnylam Blood Pressure Drug Aces In Mid-Stage Trial, Analyst Says Zilebesiran As Promising Opportunity In Addressing Global Hypertension Challenges
Via Benzinga
11 'Granolas' Stocks Outperform Magnificent 7 With Lower Volatility, Higher Yields
Via Benzinga
Celldex Stock Hits 11-Month High, Up 19%, On A Promising New Hives Treatment
Via Investor's Business Daily
This Drug By Roche And Novartis Reduces Allergic Reactions Across Multiple Foods For People With Food Allergies
Via Benzinga
New England Journal of Medicine Publishes Phase III Data Showing Xolair Significantly Reduced Allergic Reactions Across Multiple Foods in People With Food Allergies
From Genentech
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.